Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;43(3):489-498.
doi: 10.1016/j.ccm.2022.05.003.

Advances in Sepsis Care

Karen E Jackson  1 , Matthew W Semler  2
Affiliations
Review

Advances in Sepsis Care

Karen E Jackson et al. Clin Chest Med. 2022 Sep.

Abstract

This review article summarizes current scientific evidence regarding the treatment of sepsis. We highlight recent advances in sepsis management with a focus on antibiotics, fluids, vasopressors, and adjunctive therapies such as corticosteroids and renal replacement therapy.

Keywords: Critical care; Sepsis; Septic shock.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declared no potential conflicts of interest with the current work.

Figures

Figure 1.
Figure 1.. Effect of sepsis therapies on mortality in large, randomized trials.
Odds ratios are unadjusted and calculated from raw data reported in trials unless specified otherwise. Panel a – mortality from the Rivers and ProCESS trials are 60-day mortality, ARISE and ProMISE are 90-day mortality. ProMISE is an adjusted OR. Panel b – SPLIT, SALT, SALT-ED and SMART show ORs for in-hospital mortality. Panel c – SAFE and ALBIOS show ORs for 28-day mortality. Panel d – Annane and CORTICUS report 28-day mortality in non-responders, ADRENAL and APROCCHSS report 90-day mortality. Annane and ADRENAL are adjusted ORs. Panel e – ELAIN, STAART-AKI, and IDEAL-ICU report 90-day mortality, AKIKI reported 60-day mortality. Panel f – CITRIS ALI and VITAMINS report 28-day mortality, VICTAS reported 180-day mortality.
See this image and copyright information in PMC

References

    1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801. doi:10.1001/jama.2016.0287 - DOI - PMC - PubMed
    1. Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet. 2020;395(10219):200–211. doi:10.1016/S0140-6736(19)32989-7 - DOI - PMC - PubMed
    1. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference: Crit Care Med. 2003;31(4):1250–1256. doi:10.1097/01.CCM.0000050454.01978.3B - DOI - PubMed
    1. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*: Crit Care Med. 2006;34(6):1589–1596. doi:10.1097/01.CCM.0000217961.75225.E9 - DOI - PubMed
    1. Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program. Crit Care Med. 2014;42(8):7. - PubMed

Publication types

MeSH terms

Substances